Bionano Genomics (BNGO) Non-Current Debt (2018 - 2021)

Bionano Genomics has disclosed Non-Current Debt across 4 years of filings, most recently posting $14.9 million for Q1 2021.

• Non-Current Debt for Q1 2021 came in at $14.9 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2021 was $14.9 million (changed N/A YoY), and the FY2020 annual result was $16.3 million, changed N/A from the prior year.
• Non-Current Debt came in at $14.9 million for Q1 2021 at Bionano Genomics, down from $16.3 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $18.8 million in Q3 2019 to a low of $1.8 million in Q2 2020.
• The 4-year median for Non-Current Debt is $14.9 million (2021), against an average of $12.1 million.
• Across the five-year window, Non-Current Debt jumped 108.44% in 2019 and slumped 90.55% in 2020, its largest moves.
• Bionano Genomics' Non-Current Debt stood at $9.0 million in 2018, then jumped by 107.96% to $18.8 million in 2019, then fell by 13.06% to $16.3 million in 2020, then declined by 8.94% to $14.9 million in 2021.
• The last three Non-Current Debt figures came in at $14.9 million (Q1 2021), $16.3 million (Q4 2020), and $1.8 million (Q3 2020), per Business Quant data.